Completed PHASE1 INTERVENTIONAL 3-arm NCT01617239

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

A Phase I, Open Label, Randomized Study in Healthy Adults to Compare Safety and Immunogenicity of Different Administration Schedules of Virosomal Influenza Vaccine

Sponsor: Crucell Holland BV

Conditions Influenza

Interventions Virosomal influenza vaccine

Updated 5 times since 2017 Last updated: Aug 19, 2014 Started: Jun 30, 2012 Primary completion: Jun 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01617239, this PHASE1 trial focuses on Influenza and remains completed. Sponsored by Crucell Holland BV, it has been updated 5 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Crucell Holland BV

Data source: Crucell Holland BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Antwerp, Belgium